What is the best HIV pre‑exposure prophylaxis (PrEP) medication to prescribe for a patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Best HIV PrEP Medication

Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) once daily is the recommended first-line oral PrEP medication for most patients, with injectable cabotegravir every 8 weeks or lenacapavir every 6 months as superior alternatives when available and appropriate. 1, 2, 3

Primary Recommendation: Oral PrEP

TDF/FTC (Truvada or generic) taken once daily remains the gold standard oral PrEP regimen with the highest level of evidence (AIa rating) for all populations at risk for HIV acquisition 1, 2. This includes:

  • Cisgender men and women
  • Transgender individuals
  • People who inject drugs
  • Pregnant or breastfeeding individuals (AIIa evidence rating) 2

Dosing Strategy

  • Start with a double dose (2 pills) on day 1 for men who have sex with men (MSM), followed by single daily dosing 1
  • For MSM: Protection achieved within 24 hours of the double dose for rectal exposures 1
  • For vaginal/neovaginal exposures: Protection requires approximately 7 days of daily dosing 1, 2
  • Continue for 2 days after last rectal exposure or 7 days after last vaginal exposure when discontinuing 1

Alternative Oral Option: On-Demand (2-1-1) Dosing

Only for cisgender men having planned receptive anal sex (AIa evidence rating) 1, 2:

  • 2 pills taken 2-24 hours before sex
  • 1 pill 24 hours after first dose
  • 1 pill 48 hours after first dose
  • Continue daily if ongoing sexual activity until 2 doses after last exposure

Superior Alternative: Long-Acting Injectable PrEP

Lenacapavir (Most Recent, Highest Quality Evidence)

Lenacapavir administered subcutaneously every 6 months represents the most convenient and effective PrEP option currently available 3, 4. This is the newest FDA-approved option (2025) with demonstrated superiority over oral PrEP.

Dosing Protocol 3:

  • Loading: Day 1: 927 mg SC (two 1.5-mL injections) + 600 mg oral; Day 2: 600 mg oral
  • Maintenance: 927 mg SC every 6 months (±2 weeks)
  • Time to protection: 2 hours after day 2 oral dose if loading completed properly 3
  • Eligibility: Weight ≥35 kg (≥77 lbs) and at risk for HIV 3

Key advantages:

  • Twice-yearly dosing eliminates daily adherence burden
  • Demonstrated zero HIV infections in phase III trials 4
  • High adherence rates across diverse populations 4
  • Subcutaneous (not intramuscular) administration

Cabotegravir

Injectable cabotegravir every 8 weeks is recommended for cisgender men and transgender women who have sex with men (AIa evidence rating) 1.

Dosing 1:

  • 600 mg IM gluteal injections
  • Initial 4-week interval between first 2 injections
  • Then every 8 weeks thereafter
  • Oral lead-in optional (BIb evidence rating) 1

This option showed superiority over daily oral TDF/FTC in randomized trials of 4,570 MSM and transgender women, with the study stopped early for efficacy 1.

Special Population Considerations

MSM with Kidney or Bone Concerns

Tenofovir alafenamide/emtricitabine (TAF/FTC) daily is recommended for MSM with 1:

  • Creatinine clearance 30-60 mL/min
  • History of osteopenia or osteoporosis
  • High risk for these complications
  • Evidence rating: BIa

Important caveat: TAF/FTC efficacy is not superior to TDF/FTC; it simply has a better renal and bone safety profile 1. Do not use TAF/FTC for on-demand dosing - no supporting data 1.

Pregnant or Breastfeeding Individuals

  • First choice: Daily TDF/FTC (AIIa evidence rating) 1, 2
  • Alternative: Long-acting cabotegravir has growing safety data and can be used (BIIa evidence rating) 2
  • Lenacapavir: Emerging safety data support use in pregnancy/breastfeeding (BIIa evidence rating) 2

Required Pre-Initiation Testing

Before starting any PrEP regimen 1:

Mandatory:

  • Combined HIV antibody/antigen test (within 7 days)
  • HIV RNA if acute infection suspected
  • Serum creatinine/estimated creatinine clearance
  • Hepatitis B surface antigen
  • Hepatitis C antibody
  • STI screening (gonorrhea, chlamydia by NAAT - genital and extragenital sites)
  • Pregnancy test for individuals of childbearing potential

For MSM and people who inject drugs:

  • Hepatitis A antibody (if not immune)

Monitoring Schedule

Oral PrEP (TDF/FTC or TAF/FTC) 1

At 1 month:

  • HIV antibody/antigen test

Every 3 months:

  • HIV antibody/antigen test
  • STI screening (gonorrhea, chlamydia, syphilis)
  • Pregnancy testing if applicable
  • Creatinine clearance at first quarterly visit, then annually (more frequently if CrCl <90 mL/min or risk factors present)

Annually:

  • Hepatitis C antibody (every 3-6 months for people who inject drugs or MSM using drugs during sex)

Injectable Lenacapavir 3

Every 6 months (at injection visits):

  • Rapid point-of-care HIV test before injection (do not delay injection)
  • Laboratory HIV antibody/antigen test (send but don't wait for results)
  • STI screening every 4 months (every other injection)
  • Liver enzymes every 6 months

Injectable Cabotegravir 1

Every 8 weeks (at injection visits):

  • Rapid HIV test before injection
  • Laboratory HIV antibody/antigen test
  • STI screening every 4 months
  • Liver enzymes every 6 months

Critical Pitfalls to Avoid

  1. Never initiate PrEP with suspected acute HIV infection - obtain HIV RNA first 1
  2. Do not use TAF/FTC for on-demand dosing - only TDF/FTC has supporting data 1
  3. Do not use on-demand dosing for vaginal/neovaginal exposures - only validated for receptive anal sex in cisgender men 1, 2
  4. When switching from tenofovir-based PrEP to lenacapavir, screen for hepatitis B - tenofovir treats HBV, so alternative HBV therapy needed if infected 3
  5. For lenacapavir, if both oral loading doses are missed, protection is delayed 21-28 days (versus 2 hours if completed) 3
  6. Monitor creatinine more frequently (every 3-6 months) in patients >50 years, baseline CrCl <90 mL/min, or with diabetes/hypertension 1

Practical Algorithm for Selection

Step 1: Assess patient preference for oral vs. injectable

  • If prefers oral → TDF/FTC daily (or TAF/FTC if kidney/bone concerns in MSM)
  • If prefers injectable → Lenacapavir (every 6 months) or cabotegravir (every 8 weeks)

Step 2: For oral PrEP in MSM, assess sexual activity pattern

  • Planned receptive anal sex → Offer on-demand 2-1-1 dosing option
  • Unpredictable timing or other exposures → Daily dosing required

Step 3: Special populations

  • Pregnant/breastfeeding → Daily TDF/FTC first-line
  • MSM with CrCl 30-60 or bone disease → TAF/FTC daily
  • Adherence concerns → Strongly favor injectable options

Step 4: Confirm no contraindications

  • Rule out acute/chronic HIV infection
  • Check for significant drug interactions (especially with lenacapavir and CYP3A inducers)
  • Assess hepatitis B status if switching from tenofovir-based regimen

References

Related Questions

How does pre‑exposure prophylaxis (PrEP) work to prevent HIV infection?
What is the recommended antiretroviral therapy and overall management for a 10‑year‑old male with HIV infection?
What is the risk of HIV transmission after a solid (non‑hollow) needle exposure with no visible blood, and what post‑exposure prophylaxis is recommended?
Can Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) be used as pre-exposure prophylaxis (PrEP) in sexually active adults at high risk of HIV acquisition with impaired renal function?
Is HIV transmission possible when a band‑aid that briefly contacts microscopic blood from a finger is applied to a bleeding venipuncture site, and how does this risk compare to a needle‑stick exposure?
Do toilets need to be cleaned after each use by a patient who has completed MRSA infection therapy and has no open wounds?
What counseling should be provided to a patient starting Orgovyx (relugolix) for prostate cancer?
Can hydrochlorothiazide be used without harming the liver in a patient with rheumatoid arthritis and autoimmune hepatitis?
How often may an adult safely take a tablet containing 5 mg oxycodone and 325 mg acetaminophen?
When should a cardiac event monitor be ordered instead of continuous outpatient monitoring for a patient?
In a patient with urinary retention, which antipsychotic medication is most appropriate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.